Prognosis
Gilead Says Remdesivir Linked to a Reduction in Mortality Risk
- Company analysis looked at trial data and real-world treatment
- Drug is found to extend survival by more than standard care
This article is for subscribers only.
Gilead Sciences Inc.’s remdesivir may help severely ill Covid-19 patients survive the deadly infection, according to a comparison of the company’s clinical-trial results to a real-world group of people battling the disease.
Patients getting remdesivir as part of Gilead’s pivotal study, known as SIMPLE-Severe, were 62% less likely to die within 14 days than a group that wasn’t part of the trial, the company said in a statement. The data were being presented at the International AIDS Society’s Virtual Covid-19 Conference.